Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring
Author:
Affiliation:
1. CHU Rennes, Univ Rennes; Rennes France
2. CHU Rennes, Univ Rennes, INSERM; Rennes France
3. CHU Rennes, Univ Rennes, INSERM, Institut NUMECAN (Nutrition Metabolisms and Cancer); Rennes France
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15046/fullpdf
Reference30 articles.
1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002
2. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004
3. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study;Valk;Gut,2014
4. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease;Lemaitre;JAMA,2017
5. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease;Williams;Aliment Pharmacol Ther,2014
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review;Journal of Crohn's and Colitis;2023-11-01
2. Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers;Cancer Chemotherapy and Pharmacology;2023-07-06
3. Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors;World Journal of Clinical Cases;2023-04-26
4. Therapeutic drug monitoring of biologics in inflammatory bowel disease;Canadian IBD Today;2023-04-11
5. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases;Therapeutic Drug Monitoring;2023-04-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3